Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluer effektiviteten og sikkerheten til LivPhcD-kapsler i NAFLD-emner

29. september 2026 oppdatert av: TCM Biotech International Corp.

Multisenter, randomisert, dobbeltblind, placebokontrollert studie for å evaluere effektiviteten og sikkerheten til LivPhcD-kapsler i NAFLD-emner

Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse. Early-stage NAFLD does not usually cause any harm but nonalcoholic steatohepatitis (NASH) can lead to serious liver damage, including fibrosis or cirrhosis. Nearly 25% of the world's population is affected by NAFLD.

There are no FDA-approved medications for the treatment of NAFLD currently and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients.

LivPhcD™ capsule have shown hepatoprotective effects in both animal and human data. This study aims to investigate the effects of LivPhcD™ capsule in hepatocellular lipid content using Fibroscan.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

110

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Not Required For This Country
      • Taipei, Not Required For This Country, Taiwan, 221
        • National Taiwan University Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

20 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female between 20 and 75 years of age.
  2. Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel.
  3. Has a body mass index (BMI) ≥20 kg/m^2 and ≤50 kg/m^2 and stable weight for the past 3 months
  4. CAP ≥ 238 db/m
  5. Fibro scan (transient elastography) F0~F3

Exclusion Criteria:

  1. Pregnant or breastfeeding or planning to become pregnant or unwilling to use an acceptable contraceptive method to avoid pregnancy during the study period
  2. Type 1 diabetes mellitus.
  3. History of other causes of chronic liver disease [autoimmune, primary biliary cirrhosis, HBV (HBsAg positive) and HCV, Wilson disease, alpha-1-antitrypsin deficiency, hemochromatosis etc.
  4. Use of medications that could induce steatosis, such as estrogen or other hormonal replacement therapy, amiodarone, methotrexate, tamoxifen, raloxifene, pharmacological doses of oral glucocorticoids (≥10 mg per day of prednisone or equivalent), or chloroquine.
  5. Use of vitamin E (doses ≥800 IU/dy) or pioglitazone or SGLT2 inhibitor or GLP-1 agonists any FDA-approved drug for NASH to be approved during the study.
  6. Has significant systemic or major illnesses other than liver disease, ex: recent events (≤6 months before study entry) of congestive heart failure, unstable coronary artery disease, serious COPD, renal failure and need hemodialysis, stroke, transient ischemic attack, or organ transplantation
  7. Known alcohol abuse or alcohol use disorder (>20 g/day for women; >30 g/day for men)
  8. Has the abnormal data including: fasting TG >400 mg/dL ; ALT or GGT>5.0 x ULN;Bilirubin >2 x ULN,unless due to an alternative etiology such as Gilbert's syndrome; INR ≥1.3; Albumin < LLN; Platelet <0.95x LLN
  9. Subjects with hemoglobin A1c (HbA1c) >8.5% within 3 months before study entry
  10. Plan to have major surgery during the study period (bariatric surgery, biliary diversion surgery)
  11. Participation in any other investigational clinical trial within 30 days of entry to this protocol(including drugs, medical devices, novel medical technologies, food, and lifestyle interventions affecting diet, exercise, and circadian rhythm investigational clinical trial.);
  12. History of HIV

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Placebo without active ingredient

Placebo matching LivPhcD cap.

Aktiv komparator: 2 cap.LivPhcD/per day

515mg/LivPhcD cap. 2 cap./per day

2 caps. LivPhcD cap. after meal, once a day

Aktiv komparator: 4 cap.LivPhcD/per day

515mg/LivPhcD cap. 4 cap./per day, BID

4 caps. LivPhcD cap. after meal, BID

Aktiv komparator: 6 cap.LivPhcD/per day

515mg/LivPhcD cap. 6 cap./per day, TID

6 caps. LivPhcD cap. after meal, TID

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Reduction of Liver Fat
Tidsramme: 36 weeks

Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fat by CAP(Controlled Attenuation Parameter)

36 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in liver fat at least 30% reduction
Tidsramme: 24 weeks and 36 weeks

Between group difference in the proportion of patients with ≥ 30% reduction of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fat at least 1 stage reduction
Tidsramme: 24 weeks and 36 weeks

Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fat
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change of liver fat by CAP

24 weeks and 36 weeks
Stable in liver fat
Tidsramme: 24 weeks and 36 weeks

Between group difference in the proportion of patients with stable of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fibrosis at least 10% reduction
Tidsramme: 24 weeks and 36 weeks

Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Change in liver fibrosis at least 1 stage reduction
Tidsramme: 24 weeks and 36 weeks

Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Stable in liver fibrosis
Tidsramme: 24 weeks and 36 weeks

Between group difference in the proportion of patients with stable reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Change in liver fibrosis
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change of FIB-4

24 weeks and 36 weeks
Change in ALT
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of ALT

24 weeks and 36 weeks
Change in AST
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of AST

24 weeks and 36 weeks
Change in GGT
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of GGT

24 weeks and 36 weeks
Change in AP
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of AP

24 weeks and 36 weeks
Change in Bilirubin
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Bilirubin

24 weeks and 36 weeks
Change in Triglyceride
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Triglyceride

24 weeks and 36 weeks
Change in Total Cholesterol
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Total Cholesterol

24 weeks and 36 weeks
Change in HDL-C
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of HDL-C

24 weeks and 36 weeks
Change in LDL-C
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of LDL-C

24 weeks and 36 weeks
Change in TNF-α
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of TNF-α

24 weeks and 36 weeks
Change in C-Reactive Protein
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of C-Reactive Protein

24 weeks and 36 weeks
Change in Albumin
Tidsramme: 24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Albumin

24 weeks and 36 weeks
Occurrence of adverse events and serious adverse events
Tidsramme: 24 weeks and 36 weeks

Between group difference in the occurrence of adverse events and serious adverse events.

24 weeks and 36 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. desember 2023

Primær fullføring (Faktiske)

22. desember 2025

Studiet fullført (Faktiske)

22. januar 2026

Datoer for studieregistrering

Først innsendt

28. mai 2023

Først innsendt som oppfylte QC-kriteriene

25. juni 2023

Først lagt ut (Faktiske)

5. juli 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • LivPhcD-001

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere